Thu, Dec 18, 2014, 5:53 PM EST - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Emisphere Technologies, Inc. Message Board

  • nopr_iremis nopr_iremis Sep 28, 2011 2:01 PM Flag

    Holy EMIS - PART II

    In recent times is that raised questions about new adverse reactions to the product, which, according to us analysts can make it even easier for Nordic Bioscience and partner Novartis to make room on the market. Claus Christiansen do not believe, however, that the rare cases of hip fracture associated with ingestion of bifosfonater makes a difference on the market opportunity is created.
    "Bifosfonater is excellent medicines. Penicillin looks after all people a rare occasion, but at the same time save the millions of people, "says Claus Christiansen.
    Nordic Bioscience ambition is that the medicinal product may give the patient more advantages than the current treatments offer. "Oral calcitonin gene must have something extra, work better and be more secure. It must have something extra, which bifosfonaterne does not have, and it must be better than the nasale, and there is no doubt about it here, "says Morten Karsdal, Managing Director of Nordic Bioscience.
    Fails both He points out that Nordic Bioscience has a chance to win both markets, because about 60 percent of the people who have bone, osteoporosis, also has osteoarthritis. "If we must choose a medicinal product which has the effect of two different tissues, and one can understand how it works, you will of course choose what also takes pains. We believe that the market is huge, "says Morten Karsdal. Claus Christiansen has earlier into the accounts of his personal company described the potential of this medication can increase his fortune with 3-4 billion on the basis of the anticipated future sales.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
 
EMIS
0.3401-0.0219(-6.05%)Dec 18 3:19 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.